Insights

View our latest blog posts, webinars and news stories below

New White Paper: A Vision for the Future of Medicare Advantage Supplemental Benefits: Advancing Value, But Validating Results

Medicare Advantage plans in the United States continue to explode in popularity, now reaching over 30 million Americans, due to the broad appeal of supplemental benefits that can be offered by plans to enrollees. What started off as a core set of benefit offerings, including dental, vision, and over-the-counter medications, has recently been expanded by … Read more

New Task Force Endorses Legislation to Save Rare Disease Treatments 

The Save Rare Treatments Task Force, a new multi-sector public policy and advocacy collaboration convened by Leavitt Partners, an HMA Company, publicly launched this week and today released a letter of support for recently introduced, bipartisan, bicameral legislation. The Task Force is comprised of organizations representing persons living with rare diseases, biopharmaceutical innovators, and other … Read more

A Vision for Consumer Engagement in Health 

Rebecca Nielsen, Managing Director, Leavitt Partners, an HMA CompanySpencer Morrison, Associate Principal, Leavitt Partners, an HMA Company  PillPack boasts the tagline, “Pharmacy Simplified.” The mail-order pharmacy successfully streamlined the activities associated with managing medications. It illuminated for its customers what medications they needed to take next, and at what time, by packaging meds in a … Read more

New White Paper: “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward”

In “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward,” Rebecca Nielsen, Brooke Zollinger, and Sarah Johnson from Leavitt Partners explore the feasibility of operationalizing an aggregated precision investment (API) model for social determinants of health (SDOH) interventions. The authors derive their findings from subject matter expert interviews, conversations with potential aggregators, and relevant secondary research. This article enumerates … Read more

Amy Comstock Rick Joins Leavitt Partners, an HMA Company

Amy Comstock Rick, former president and chief executive officer (CEO) of the Food and Drug Law Institute (FDLI), joined Leavitt Partners, an HMA Company as a principal on March 20. Rick has over 30 years of experience leading organizations, executing strategy, transforming organizational culture, building consensus, and advocating policies across constituencies. “Amy is widely respected … Read more

New white paper from Medicines Development Modernization Initiative

Data science and digital health in clinical development and operations: impact, challenges, and calls to action for the drug development ecosystem In this paper, the Medicines Development Modernization Initiative discuss how three medicines development tools (MDTs) – artificial intelligence (AI) and machine learning (ML) algorithms, digital health tools (DHTs), and augmentation of randomized controlled trial … Read more

Supporting Pharmacy Data Interoperability: An Imperative for Patient Access and Outcomes

Pharmacy provision of clinical services is important to patient access and outcomes. As patients access more services from pharmacies, the data interoperability of those pharmacies becomes more important to the healthcare system at-large. Pharmacy teams’ ability to provide optimal care and meaningfully contribute to the value-based care transformation depends on their ability to access and … Read more

Leavitt Partners Report Identifies Strategies to Improve Pharmacy Data Interoperability

Today, Leavitt Partners, an HMA Company released a report outlining steps federal and state policymakers, technology and electronic health record (EHR) companies, health plans, pharmacies, and other healthcare providers can take to strengthen pharmacy data interoperability. As patients access more services from pharmacies, the data interoperability of those pharmacies becomes increasingly important to patients and … Read more